The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the “most important” variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.

Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg) / Nyssen O.P.; Pratesi P.; Spinola M.A.; Jonaitis L.; Perez-Aisa A.; Vaira D.; Saracino I.M.; Pavoni M.; Fiorini G.; Tepes B.; Bordin D.S.; Voynovan I.; Lanas A.; Martinez-Dominguez S.J.; Alfaro E.; Bujanda L.; Pabon-Carrasco M.; Hernandez L.; Gasbarrini A.; Kupcinskas J.; Lerang F.; Smith S.M.; Gridnyev O.; Leja M.; Rokkas T.; Marcos-Pinto R.; Mestrovic A.; Marlicz W.; Milivojevic V.; Simsek H.; Kunovsky L.; Papp V.; Phull P.S.; Venerito M.; Boyanova L.; Boltin D.; Niv Y.; Matysiak-Budnik T.; Doulberis M.; Dobru D.; Lamy V.; Capelle L.G.; Nikolovska Trpchevska E.; Moreira L.; Cano-Catala A.; Parra P.; Megraud F.; O'Morain C.; Ortega G.J.; Gisbert J.P.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 12:9(2023), pp. 1427.1-1427.18. [10.3390/antibiotics12091427]

Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg)

Vaira D.;Saracino I. M.;Pavoni M.;Fiorini G.;Venerito M.;
2023

Abstract

The segmentation of patients into homogeneous groups could help to improve eradication therapy effectiveness. Our aim was to determine the most important treatment strategies used in Europe, to evaluate first-line treatment effectiveness according to year and country. Data collection: All first-line empirical treatments registered at AEGREDCap in the European Registry on Helicobacter pylori management (Hp-EuReg) from June 2013 to November 2022. A Boruta method determined the “most important” variables related to treatment effectiveness. Data clustering was performed through multi-correspondence analysis of the resulting six most important variables for every year in the 2013–2022 period. Based on 35,852 patients, the average overall treatment effectiveness increased from 87% in 2013 to 93% in 2022. The lowest effectiveness (80%) was obtained in 2016 in cluster #3 encompassing Slovenia, Lithuania, Latvia, and Russia, treated with 7-day triple therapy with amoxicillin–clarithromycin (92% of cases). The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth–quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin–amoxicillin–metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. Cluster analysis allowed for the identification of patients in homogeneous treatment groups assessing the effectiveness of different first-line treatments depending on therapy scheme, adherence, country, and prescription year.
2023
Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013–2022: Data from the European Registry on H. pylori Management (Hp-EuReg) / Nyssen O.P.; Pratesi P.; Spinola M.A.; Jonaitis L.; Perez-Aisa A.; Vaira D.; Saracino I.M.; Pavoni M.; Fiorini G.; Tepes B.; Bordin D.S.; Voynovan I.; Lanas A.; Martinez-Dominguez S.J.; Alfaro E.; Bujanda L.; Pabon-Carrasco M.; Hernandez L.; Gasbarrini A.; Kupcinskas J.; Lerang F.; Smith S.M.; Gridnyev O.; Leja M.; Rokkas T.; Marcos-Pinto R.; Mestrovic A.; Marlicz W.; Milivojevic V.; Simsek H.; Kunovsky L.; Papp V.; Phull P.S.; Venerito M.; Boyanova L.; Boltin D.; Niv Y.; Matysiak-Budnik T.; Doulberis M.; Dobru D.; Lamy V.; Capelle L.G.; Nikolovska Trpchevska E.; Moreira L.; Cano-Catala A.; Parra P.; Megraud F.; O'Morain C.; Ortega G.J.; Gisbert J.P.. - In: ANTIBIOTICS. - ISSN 2079-6382. - ELETTRONICO. - 12:9(2023), pp. 1427.1-1427.18. [10.3390/antibiotics12091427]
Nyssen O.P.; Pratesi P.; Spinola M.A.; Jonaitis L.; Perez-Aisa A.; Vaira D.; Saracino I.M.; Pavoni M.; Fiorini G.; Tepes B.; Bordin D.S.; Voynovan I.; Lanas A.; Martinez-Dominguez S.J.; Alfaro E.; Bujanda L.; Pabon-Carrasco M.; Hernandez L.; Gasbarrini A.; Kupcinskas J.; Lerang F.; Smith S.M.; Gridnyev O.; Leja M.; Rokkas T.; Marcos-Pinto R.; Mestrovic A.; Marlicz W.; Milivojevic V.; Simsek H.; Kunovsky L.; Papp V.; Phull P.S.; Venerito M.; Boyanova L.; Boltin D.; Niv Y.; Matysiak-Budnik T.; Doulberis M.; Dobru D.; Lamy V.; Capelle L.G.; Nikolovska Trpchevska E.; Moreira L.; Cano-Catala A.; Parra P.; Megraud F.; O'Morain C.; Ortega G.J.; Gisbert J.P.
File in questo prodotto:
File Dimensione Formato  
antibiotics-12-01427-v3.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.37 MB
Formato Adobe PDF
1.37 MB Adobe PDF Visualizza/Apri
antibiotics-12-01427-s001.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2 MB
Formato Zip File
2 MB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/958123
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact